VEA
ALXN

Virtus ETF Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Virtus ETF Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,749
Closed -$505K – 406
2021
Q2 		$505K Sell
2,749
-1,260
-31% -$216K 0.21% 147
2021
Q1 		$613K Buy
4,009
+115
+3% +$17.8K 0.26% 121
2020
Q4 		$608K Sell
3,894
-1,453
-27% -$187K 0.25% 111
2020
Q3 		$612K Buy
5,347
+181
+4% +$19.5K 0.32% 113
2020
Q2 		$580K Sell
5,166
-478
-8% -$50.7K 0.27% 123
2020
Q1 		$507K Sell
5,644
-457
-7% -$44.9K 0.21% 169
2019
Q4 		$660K Buy
6,101
+38
+0.6% +$4.06K 0.11% 164
2019
Q3 		$594K Sell
6,063
-801
-12% -$90.3K 0.12% 173
2019
Q2 		$899K Buy
+6,864
New +$885K 0.19% 154
2016
Q4 		– Sell
-4,745
Closed -$581K – 201
2016
Q3 		$581K Buy
4,745
+598
+14% +$77K 0.28% 64
2016
Q2 		$484K Buy
4,147
+980
+31% +$139K 0.36% 61
2016
Q1 		$441K Hold
3,167
– – 0.61% 46
2015
Q4 		$604K Buy
+3,167
New +$553K 1.66% 18

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Virtus ETF Advisers's ALXN Position: Q3 2021 in Review

Virtus ETF Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,749 shares — an estimated $505K sold.

Virtus ETF Advisers first reported a position in ALXN in Q4 2015 and held it in 13 quarters. The position peaked at $899K in Q2 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Virtus ETF Advisers reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,749 Alexion Pharmaceuticals shares in Q3 2021, an estimated $505K.
  • Virtus ETF Advisers first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 13 quarters.
  • Virtus ETF Advisers's Alexion Pharmaceuticals position peaked at $899K in Q2 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Virtus ETF Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.